The webinar took place earlier this month and featured two new studies using WWARN-hosted clinical trial data showing that the dosing of the 8-aminoquinolin drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.
- Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
- Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
- Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics